Liquid Biopsy For Cancer Diagnostics Market Growth Is Accelerating As Industry Transformation Continues
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Liquid Biopsy For Cancer Diagnostics Market Expected To Reach $22.99 Billion By 2030 At 16.4% CAGR
The market for liquid biopsies in cancer diagnostics has experienced substantial expansion lately, projected to increase from $10.75 billion in 2025 to $12.52 billion in 2026, reflecting a compound annual growth rate (CAGR) of 16.4%. This recent growth trajectory is influenced by several factors, including the inherent limitations associated with traditional tissue biopsy methods, an escalating prevalence of lung and breast cancer diagnoses, the increasing uptake of molecular diagnostic tools for cancer, a heightened demand for detecting cancer in its nascent stages, and a surge in clinical investigations within the field of oncology diagnostics.
The market for liquid biopsies in cancer diagnostics is poised for substantial expansion over the coming period, projecting a rise to $22.99 billion by 2030, fueled by a compound annual growth rate of 16.4%. This projected increase is largely driven by the widening application of liquid biopsies in standard cancer screening protocols, a heightened emphasis on individualized cancer treatment strategies, greater utilization for tracking treatment efficacy, escalating investments in the field of cancer diagnostics, and an increased deployment in the detection of gastrointestinal and ovarian cancers. Key developments anticipated during this forecast timeframe encompass the expanding use of liquid biopsies for diagnosing lung cancer, a surge in the adoption of blood-based screening techniques for cancer, a growing need for continuous cancer monitoring, the broadening application scope of liquid biopsies across various cancer types, and a prevalent shift in clinical practice towards favoring less invasive diagnostic methods.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12205&type=smp
Liquid Biopsy For Cancer Diagnostics Market Demand Drivers: What Is Fueling Industry Growth?
The expanding prevalence of cancer is anticipated to be a significant catalyst for the advancement of the liquid biopsy market within the realm of cancer diagnostics. Cancer, a complex collection of diseases, can originate in virtually any part of the body as abnormal cells multiply without control, breaching their normal confines and subsequently metastasizing to distant sites or invading adjacent tissues. This escalating cancer burden underscores the necessity for advanced diagnostic tools like liquid biopsy, capable of facilitating early detection, assessing individual patient risk, and monitoring treatment efficacy. Liquid biopsy offers a comprehensive, real-time view of tumor evolution, including the identification of therapeutic targets and resistance mechanisms, by analyzing circulating tumor cells or their byproducts released from both primary and metastatic lesions, thus capturing the multifaceted nature of the disease. Supporting this trend, data from the National Cancer Institute indicated approximately 18.1 million cancer survivors in the U.S. as of May 2024, with projections suggesting this number will climb to 22.5 million by 2032 and anticipates a rise in new cancer cases to 29.9 million annually by 2040, accompanied by an estimated 15.3 million cancer-related fatalities, reinforcing the market’s upward trajectory due to increasing cancer incidence.
Liquid Biopsy For Cancer Diagnostics Market Segment Analysis Highlighting Growth Areas
The liquid biopsy for cancer diagnostics market covered in this report is segmented –
1) By Type: Product, Services
2) By Sample: Blood, Urine, Saliva
3) By Cancer: Lung Cancer, Breast Cancer, Colon Cancer, Other Cancers
4) By End-User: Hospitals, Diagnostic Centers, Other End-Users
Subsegments:
1) By Product: Circulating Tumor Cells (CTCs) Detection Kits, Circulating Tumor DNA (ctDNA) Detection Kits, Exosome Isolation Kits, Sample Collection Devices
2) By Services: Testing Services, Analytical Services, Bioinformatics Services
Liquid Biopsy For Cancer Diagnostics Market Innovation Trends: Which Developments Are Transforming The Industry?
Key players in the liquid biopsy for cancer diagnostics sector are prioritizing the creation of groundbreaking technologies, specifically advanced liquid biopsy assays. These sophisticated diagnostic tools examine diverse elements within biological fluids like blood to identify and define unique cancer-related markers. As an illustration, in November 2023, Illumina Inc., a prominent American firm in the DNA sequencing field, unveiled ‘TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2)’. This groundbreaking research assay enables non-invasive, thorough genomic analysis of circulating tumor DNA found in blood samples, aiming to streamline user implementation and deepen the understanding derived from cancer research.
Liquid Biopsy For Cancer Diagnostics Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the liquid biopsy for cancer diagnostics market are F. Hoffman La Roche Ltd., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., The Menarini Group, Bio-Rad Laboratories Inc., QIAGEN Inc., Exact Sciences Corporation, Bio-Techne Corporation, ArcherDX Inc., Neogenomics Laboratories Inc., Guardant Health Inc., Myriad Genetics Inc., Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., Biocartis Group NV, Biodesix Inc., MDx Health Inc., Sysmex Inostics Inc., Biocept Inc., Agena Bioscience Inc., Laboratory for Advanced Medicine (LAM) Inc., MiRXES Pte Ltd., Inivata Limited, Resolution Bioscience Inc., SAGA Diagnostics AB, NuProbe Inc., Personal Gemone Diagnostics Inc., Pathway Genomics Corporation, Angle PLC
Access The Complete Liquid Biopsy For Cancer Diagnostics Market Report:
Liquid Biopsy For Cancer Diagnostics Market Largest Region By Revenue And Market Share
North Americawas the largest region in the liquid biopsy for cancer diagnostics market in 2025. Asia-Pacificis expected to be the fastest-growing region in the liquid biopsy for cancer diagnostics market report during the forecast period. The regions covered in the liquid biopsy for cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
